Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

Jan Wysocki, Enrique Lores, Minghao Ye, Maria Jose Soler, Daniel Batlle*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

87 Scopus citations
Original languageEnglish (US)
Pages (from-to)1941-1943
Number of pages3
JournalJournal of the American Society of Nephrology
Volume31
Issue number9
DOIs
StatePublished - Sep 2020

Funding

This work was supported by the Joseph and Bessie Feinberg Foundation (Dr. Daniel Batlle). We thank Dr. Hong D. Xiao (Providence Portland Medical Center, Portland, OR) and Dr. Kenneth E. Bernstein (Cedars Sinai, Los Angeles, CA) for generously providing kidneys from ACE deficiency models. Dr. Daniel Batlle reports nonfinancial support from Angiotensin Therapeutics Inc., outside the submitted work. Dr. Maria Jose Soler reports personal fees from AstraZeneca, nonfinancial support from Boehringer In-gelheim, nonfinancial support from Eli Lilly, personal fees and nonfinancial support from Esteve, personal fees from FMC, personal fees from Janssen, personal fees from Mundi-pharma, and personal fees from NovoNordisk, outside the submitted work. D. Batlle was funded by National Institute of Diabetes and Digestive Kidney Diseases grant RO1DK104785.

ASJC Scopus subject areas

  • General Medicine

Cite this